Head-to-head · Cost-Efficiency Index
Transcarent vs AM Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Transcarent
Cost-first shoppers who want not applicable -- only accessible through an employer or health plan, not individual consumers.
Visit TranscarentAM Rx
Cost-first shoppers who want insured shoppers chasing brand-name GLP-1 copays, provided they choose the flat Bundle plan rather than the a-la-carte route whose true monthly cost the site doesn't fully disclose.
Visit AM RxThe verdict
Transcarent takes it, leading the Cost-Efficiency Index 43 to 42. Transcarent is a large enterprise health-navigation and benefits platform, not a consumer-facing GLP-1 provider. AM Rx still earns a C — Cost-first shoppers who want insured shoppers chasing brand-name GLP-1 copays, provided they choose the flat Bundle plan rather than the a-la-carte route whose true monthly cost the site doesn't fully disclose.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Transcarent.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Transcarent | AM Rx |
|---|---|---|
| Cost-Efficiency Index | 43/100 | 42/100 |
| Semaglutide / mo | Not disclosed | $297/mo (all doses, bundle, plus a separate fee, compounded) |
| Tirzepatide / mo | Not disclosed | $449/mo (all doses, bundle, compounded) |
| Semaglutide / yr (modeled) | — | $3,564 |
| Tirzepatide / yr (modeled) | — | $5,388 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #504 | #509 |
Transcarent
43/100Where the value is
- Backed by large-scale enterprise health infrastructure and employer/health-plan partnerships
- Weight Health program integrates behavioral, pharmacy, and surgical care rather than medication alone
The tradeoffs
- No direct-to-consumer purchase option or published price at all
- Requires employer or health plan sponsorship to access -- most readers cannot use this
AM Rx
42/100Where the value is
- Insurance coordination for brand-name Ozempic/Wegovy/Zepbound/Mounjaro, quoting copays 'as little as $25 per month'
- A flat 'Bundle' pricing option ($297 semaglutide / $449 tirzepatide after a discounted first month) avoids the ambiguity of the a-la-carte route's undisclosed ongoing membership fee
- HSA/FSA accepted
The tradeoffs
- The headline 'starting as low as $151/$216 per month' figures require a separate ongoing membership fee that AM Rx's own FAQ never discloses the amount of — unlike sibling site RoenRx, which explicitly states $135/month for the equivalent membership
- No states list is published; the only geographic restriction disclosed is exclusion of government-insurance (Medicare/Medicaid) patients
Regulatory note: the FDA issued a warning letter to FitRX, LLC dba AM RX in June 2026. We still list and link to AM Rx; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.